Dr. Bahar Ramezanpour

Chief Business Development Officer

Bahar Ramezanpour holds a Ph.D. in disruptive innovation by genetically modified technologies from the University of Amsterdam and Erasmus University of Rotterdam under the supervision of Prof. ab Osterhaus and dr. Eric Claassen.

She joined the HUB in 2017 with a background in MPA, infectious diseases and genetically modified vaccines. Prior to joining the HUB, she served as Director Business Development at ViroNovative B.V. and Sovalacc B.V., biotechnology company and life sciences consultancy respectively. In these positions, she was responsible for all the aspect of business development, including out-licensing and alliance management. Furthermore, she has been involved in the start-up and growth of several business ventures in the life sciences sector.

October 21, 2020 Webinar: Drug Discovery Powered by HUB Organo... Drug Discovery Powered by HUB Organoids and OcellO 3D Image Analysis Summary: More clinically relevant models are urgent... read more
September 04, 2020 HUB and BGI-Qingdao sign a Memorandum of Unde... Utrecht and Qingdao, Sep 4th, 2020 – Hubrecht Organoid Technology (HUB) and BGI-Qingdao announced today that they ... read more
May 27, 2020 Studying the development of ovarian cancer wi... read more